SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy

被引:14
|
作者
Faisal, Farzana A. [1 ]
Kaur, Harsimar B. [2 ]
Tosoian, Jeffrey J. [3 ]
Tomlins, Scott A. [3 ,4 ]
Schaeffer, Edward M. [5 ]
Lotan, Tamara L. [1 ,2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Brady Urol Inst, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[3] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[5] Northwestern Univ, Dept Urol, Feinberg Sch Med, Chicago, IL USA
关键词
PTEN LOSS; MEN; ERG;
D O I
10.1038/s41391-019-0139-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The SPINK1 molecular subtype is more common in African-American (AA) men with prostatic adenocarcinoma (PCa) than European Americans (EA). Studies have suggested that SPINK1 expression is associated with more aggressive disease. However, the size, follow-up, and racial diversity of prior patient cohorts have limited our understanding of SPINK1 expression in AA men. The objective was to determine the associations between SPINK1 subtype, race, and oncologic outcomes after radical prostatectomy (RP). Methods A total of 186 AA and 206 EA men who underwent RP were matched according to pathologic grade. We examined SPINK1 status by immunohistochemistry on tissue microarrays using a genetically validated assay. Cox proportional hazard analyses assessed the association of SPINK1 status with oncologic outcomes in race-specific multivariate models. A second objective was to determine the correlation between CD3/CD8 T cell densities with SPINK1 status and race, using immunostaining and automated image analysis. Results SPINK1-positive subtype was present in 25% (45/186) of AA and 15% (30/206) of EA men (p = 0.013). There were no differences in pathologic grade, pathologic stage, biochemical recurrence (BCR)-free survival, or metastasis-free survival between SPINK1-positive and SPINK1-negative tumors in the overall cohort or by race. In multivariate analyses, SPINK1 expression was not associated with BCR (AA: HR 0.99, 95% CI 0.56-1.75, p = 0.976; EA: HR 0.88, 95% CI 0.43-1.77, p = 0.720) or metastasis (AA: HR 0.79, 95% CI 0.25-2.49, p = 0.691; EA: HR 1.55, 95% CI 0.58-4.11, p = 0.381) in either AA or EA men. There were no significant differences in surrounding CD3/CD8 lymphocyte densities between SPINK1-positive and SPINK1-negative tumors in either race. Conclusions SPINK1-positive subtype is more prevalent in AA than EA men with PCa. Contrary to previous studies, we found that SPINK1 protein expression was not associated with worse pathologic or oncologic outcomes after RP in either AA men or EA men.
引用
收藏
页码:552 / 559
页数:8
相关论文
共 27 条
  • [1] SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy
    Farzana A. Faisal
    Harsimar B. Kaur
    Jeffrey J. Tosoian
    Scott A. Tomlins
    Edward M. Schaeffer
    Tamara L. Lotan
    Prostate Cancer and Prostatic Diseases, 2019, 22 : 552 - 559
  • [2] SPINK1 EXPRESSION IS ENRICHED IN AFRICAN AMERICAN PROSTATE CANCER BUT IS NOT ASSOCIATED WITH ALTERED IMMUNE INFILTRATION OR ONCOLOGIC OUTCOMES POST-PROSTATECTOMY
    Faisal, Farzana
    Kaur, Harsimar
    Tosoian, Jeffrey
    Tomlins, Scott
    Schaeffer, Edward
    Lotan, Tamara
    JOURNAL OF UROLOGY, 2019, 201 (04): : E217 - E218
  • [3] SPINK1 expression is not associated with pathologic or oncologic outcomes post-prostatectomy in race-specific cohorts
    Faisal, Farzana
    Kaur, Harsimar
    Tosoian, Jeffrey
    Schaeffer, Edward
    Lotan, Tamara
    LABORATORY INVESTIGATION, 2019, 99
  • [4] SPINK1 expression is not associated with pathologic or oncologic outcomes post-prostatectomy in race-specific cohorts
    Faisal, Farzana
    Kaur, Harsimar
    Tosoian, Jeffrey
    Schaeffer, Edward
    Lotan, Tamara
    MODERN PATHOLOGY, 2019, 32
  • [5] Comparison of oncologic outcomes post-prostatectomy of prostate cancer diagnosed on transurethral resection and prostate biopsy
    Yanada, Brendan
    Perera, Marlon
    Evans, Melanie
    Murphy, Declan
    Bolton, Damien
    Papa, Nathan
    BJU INTERNATIONAL, 2022, 129 : 40 - 41
  • [6] HIGHER GRADE PROSTATE CANCER STRATIFICATION BY ERG ONCOPROTEIN AND SPINK1 EXPRESSION IN CAUCASIAN AMERICAN AND AFRICAN AMERICAN MEN
    Farrell, James
    Young, Denise
    Degon, Michael
    Srivastava, Sudhir
    Kagan, Jacob
    Cullen, Jennifer
    Petrovics, Gyprgy
    Rosner, Inger
    McLeod, David G.
    Sesterhenn, Isabell A.
    Srivastava, Shiv
    JOURNAL OF UROLOGY, 2014, 191 (04): : E450 - E450
  • [7] Clinical-Prostate cancer Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence
    Perera, Marlon
    Lebdai, Souhil
    Tin, Amy L.
    Sjoberg, Daniel D.
    Benfante, Nicole
    Beech, Benjamin B.
    Alvim, Ricardo G.
    Touijer, Adam S.
    Jenjitranant, Pocharapong
    Ehdaie, Behfar
    Laudone, Vincent P.
    Eastham, James A.
    Scardino, Peter T.
    Touijer, Karim A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (02) : 105.e19 - 105.e23
  • [8] Characterization of ERG Rearrangements, PTEN and SPINK1 Expression in Hormone Refractory Prostate Cancer Associated with Lethal Disease
    Bakkar, A.
    Yoshimoto, M.
    Liu, S.
    Duan, Q.
    Sircar, K.
    Squire, J. A.
    Bismar, T. A.
    LABORATORY INVESTIGATION, 2010, 90 : 177A - 177A
  • [9] Characterization of ERG Rearrangements, PTEN and SPINK1 Expression in Hormone Refractory Prostate Cancer Associated with Lethal Disease
    Bakkar, A.
    Yoshimoto, M.
    Liu, S.
    Duan, Q.
    Sircar, K.
    Squire, J. A.
    Bismar, T. A.
    MODERN PATHOLOGY, 2010, 23 : 177A - 177A
  • [10] Tumor-associated trypsin inhibitor (TATI, PSTI, SPINK1) expression in prostate cancer is related to tumor grade
    Bjartell, A.
    Paju, A.
    Cao, Y.
    Laurila, T.
    Gadaleanu, V.
    Hotakainen, K.
    Stenman, U. H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 791 - 791